Beobachtungsplan, NIS 16: “Long term Documentation of the Safety and Efficacy as well as the Effects on Work Productivity in Patients with Moderate to Severe Plaque Psoriasis treated with HUMIRA® (Adalimumab) in Routine Clinical Practice (LOTOS)”

Datei

• Artikel "Beobachtungsplan, NIS 16: “Long term Documentation of the Safety and Efficacy as well as the Effects on Work Productivity in Patients with Moderate to Severe Plaque Psoriasis treated with HUMIRA® (Adalimumab) in Routine Clinical Practice (LOTOS)”"Herunterladen(PDF, 569KB, Datei ist nicht barrierefrei)